Index

Note: Page numbers of article titles are in **boldface** type.

A

A Diabetes Outcome Progression Trial (ADOPT), 91, 94, 163
ABCC8 gene mutations, 6–7
Acarbose, 97, 99, 181
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 57–61, 202–203, 206
Acidosis, lactic, metformin-induced, 89–90
Acne, in polycystic ovarian syndrome, 222
Action in Diabetes and Vascular Disease Controlled Evaluation Renal Measurement (ADREM), 206
Action in Diabetes and Vascular disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, 57–61, 202, 206, 211
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 57–61, 202–203, 206
Acute Insulin Response to Glucose, 160
ADOPT (A Diabetes Outcome Progression Trial), 91, 94, 163
ADREM (Action in Diabetes and Vascular Disease Controlled Evaluation Renal Measurement), 206
ADVANCE (Action in Diabetes and Vascular disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial, 57–61, 202, 206, 211
A3434G gene mutations, 7
Albiglutide, 110–111, 116–117
Albumin/creatinine ratio, 209
Alogliptin, 118, 122, 181
Alopecia, in polycystic ovarian syndrome, 222
Alpha-glucosidase inhibitors, 97, 99, 181
American Association of Clinical Endocrinologists, insulin therapy guidelines of, 161–164
American College of Sports Medicine, physical activity guidelines of, 73
American Diabetes Association, insulin therapy guidelines of, 161–163
American Diabetes Association-European Association for the Study of Diabetes position statement, 62
 Amitriptyline, 208
Amylinomimetics, 181
Analog preparations, insulin, 170
Androgen Excess Society criteria, 226
Angiotensin receptor blockers, 189–190, 211
Angiotensin-converting enzyme inhibitors, 189–190, 211
1,5-Anhydroglucitrol measurement, 140
Anovulation, in polycystic ovarian syndrome, 221–235
Antidepressants, 208
Antihypoglycemics, oral. See Oral antihypoglycemics.
Antimüllerian hormone, in polycystic ovarian syndrome, 226
Antipsychotics, atypical, diabetes mellitus due to, 9
Antiretroviral drugs, diabetes mellitus due to, 10
Anxiety, 193
Aripiprazole, diabetes mellitus due to, 9
Artificial sweeteners, 77–78
Aspirin, 203–204
Atherosclerosis, prevention of, 191–192
Autoimmune diabetes mellitus. See Diabetes mellitus, type 1.
Autonomic neuropathy, 207

B
Baltimore Longitudinal Study of Aging, 5
Basal insulin therapy, 147–148, 171, 173
Bile acid sequestrants, 97–99, 181
Blindness, 48–50, 54, 204–206
Blood glucose, hemoglobin A1c correlation with, 36
Blood glucose monitoring
  accuracy of, 38
  continuous, 39–42, 152
  decision support in, 39
  implementation of, 38–39
  in type 1 diabetes mellitus, 152
  in type 2 diabetes mellitus, 164–165
  internet systems for, 17–33
  methods for, 35–45
Bolus calculator, 39
Bolus insulin therapy, 148, 173–178
Bromocriptine mesylate, 98–99, 181

C
Calcineurin inhibitors, diabetes mellitus due to, 9
Canagliflozin, 96, 99, 135–140, 181
Canagliflozin Cardiovascular Assessment Study (CANVAS), 140
CANagliflozin treatment and trial analysis-sulfonylurea (CANTATA-SU) trial, 96
Cancer
  endometrial, in polycystic ovarian syndrome, 222, 230
  pancreatic, 8
  risk of, metformin effects on, 89
CANTATA-SU (CANagliflozin treatment and trial analysis-sulfonylurea) trial, 96
CANVAS (Canagliflozin Cardiovascular Assessment Study), 140
Capsaicin, 208–209
Carbohydrate counting, 149, 174–177
Carbohydrate ratio, 149
Cardiovascular disease, 50–52
  in polycystic ovarian syndrome, 223, 227, 231
  incretin-induced, 122–123
  internet blood glucose monitoring systems effects on, 26
  prevention of, 191–192
  sodium glucose cotransporter 2 inhibitor effects on, 139–140
Cardiovascular Outcomes Event Trial in Type 2 Diabetes Mellitus Patients, 140
CFTR gene mutations, 8
Chlorpropamide, 91
Clomiphene citrate, for polycystic ovarian syndrome, 230
Closed-loop insulin delivery, 42
Clozapine, diabetes mellitus due to, 9
Colestevalam, 97–99, 181
Complications and targets for damage, 47–67, 187–200
  cardiovascular disease. See Cardiovascular disease.
  clinical trials involving, 52–63
  driving ability, 196
  glucose hypothesis and, 47
  hypertension, 188–191, 202–204
  lipid, 191–192, 203–204
  macrovascular disease, 50–52
  mental health, 193
  meta-analysis of, 60
  microvascular disease, 48–50
  nephropathy, 48–50, 54, 188–191, 209–212
  peripheral neuropathy, 48–50, 79, 206–209
  retinopathy, 48–50, 54, 204–206
  summary of, 195
  weight control, 193–194
Congenital diabetes, 6–7
Continuous blood glucose monitoring, 39–42
Coronary heart disease, 50–52
Corticosteroids, diabetes mellitus due to, 9
Cost-effectiveness, of internet blood glucose monitoring system, 27
Cyclosporine, diabetes mellitus due to, 9
Cyproterone acetate, for polycystic ovarian syndrome, 229
Cystic fibrosis, 7–8

D
Dapagliflozin, 96, 99, 135, 137–140, 181
DCCT (Diabetes Control and Complications Trial), 36, 52–54, 58, 146, 202, 207
Decision support, for blood glucose monitoring, 39
DECLARE-TIMI58 study, 140
Dehydroepiandrosterone sulfate, in polycystic ovarian syndrome, 226
Depression, 193
Desipramine, 208
Diabetes Control and Complications Trial (DCCT), 36, 52–54, 58, 146, 202, 207
Diabetes mellitus
  classification of, 1–16
  complications of. See Complications and targets for damage.
  diagnosis of, 1–2
  gestational, 5–6
  latent autoimmune, 3–4
  mitochondrial, 7
  monitoring of. See Blood glucose monitoring.
  monogenic, 6–7
  nonautoimmune, 7–11. See also Diabetes mellitus, type 2.
  polycystic ovarian syndrome and, 221–235
Diabetes (continued)

secondary, 7–11

treatment of

glycemic targets in, 47–67
incretin-based, 107–129
insulin for. See Insulin.
lifestyle interventions for. See Lifestyle interventions.
nonglycemic targets in, 187–200
oral antihyperglycemics for. See Oral antihypoglycemics.
primary care provider role in, 201–219
sodium glucose cotransporter 2 inhibitors for, 131–143
syndromes associated with, 11
type 1
description of, 2–4
incidence of, 145
insulin therapy for, 145–156
internet blood glucose monitoring systems for, 17–19, 22–25, 28
self-monitoring in, 37
type 2
description of, 4–5
insulin therapy for, 157–186
internet blood glucose monitoring systems for, 17–22, 24–25, 28
oral antihyperglycemics for, 87–106
self-monitored blood glucose monitoring in, 38

Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM), 94
Diabetes self-management program, 71–80
Diabetic Retinopathy Candesartan Trials (DIRECT), 206
Diabetic Retinopathy Study, 206
Diet therapy, 71–80
Digital retinal photography, 205
Dipeptidyl peptidase, therapy based on, 109, 117–122, 181
DIRECT (Diabetic Retinopathy Candesartan Trials), 206
Doleur neuropathique 4 questions, 207
DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication), 94
Driving ability, evaluation of, 196
Duloxetine, 208
Dyslipidemias, 191–192, 203–204
Everolimus, diabetes mellitus due to, 9
Exenatide and exenatide extended-release, 110–115, 122, 181
Exercise, 71–80, 149–150
Eye complications, 48–50, 54, 204–206

F
Fenofibrate, 203
Ferriman-Gallowey score, in polycystic ovarian syndrome, 222
Fibrocalculous pancreatic diabetes, 8
FIELD study, 206
Follicle-stimulating hormone, in polycystic ovarian syndrome, 224–225, 230
Free androgen index, in polycystic ovarian syndrome, 226

G
Gabapentin, 208–209
Gastric inhibitory peptide, therapy based on, 107–108
Gemfibrozil, 203
Generalized Anxiety Disorder questionnaire, 193
Genetics, of polycystic ovarian syndrome, 221–224
Gestational diabetes mellitus, 5–6
Glimepiride, 90–92, 99, 181
Glinides, 92–93, 99, 181
Glipizide, 90–92, 99
Glomerular filtration rate, 210–211
GLOWS (Glucose Lowering effect of WelChol study), 97
Glucagon-like peptide, therapy based on, 107–117
Glucokinase defects, 7
Gluconeogenesis, in kidney, 132
Glucose. See also Blood glucose; Glycemia; Glycemic control; Glycemic targets.
  kidney handling of, 132–134
  toxicity of, 180
Glucose Buddy app, 27
Glucose hypothesis, 47
Glucose Lowering effect of WelChol study (GLOWS), 97
Glyburide, 90–92, 181
Glycemia. See also Hyperglycemia; Hypoglycemia.
  control of. See Glycemic control.
  monitoring of
    internet systems for, 17–33
    methods for, 35–45
Glycemic control
  for cardiovascular disease prevention, 202
  for peripheral neuropathy, 207
  internet blood glucose monitoring systems effects on, 25–26
  markers for, 35–37
  monitoring for
    internet systems for, 17–33
    methods for, 35–45
  self-monitored
Glycemic (continued)
   internet system for, 17–33
   methods for, 37–39
Glycemic targets, 47–67
   clinical trials involving, 52–63
   glucose hypothesis and, 47
   macrovascular disease, 50–52
   meta-analysis of, 60
   microvascular disease, 48–50
Gonadotropin secretion, in polycystic ovarian syndrome, 224–225

H
Haloperidol, diabetes mellitus due to, 9
Health, Aging, and Body Composition observational study, 94
Hemochromatosis, hereditary, 8
Hemoglobin A1c
   as guide to therapy, 161–164
   canagliflozin and, 136–137
   dapagliflozin and, 137
   for monitoring, 35–37
   metformin and, 88–89
Hereditary hemochromatosis, 8
Highly concentrated insulin, 171, 178–179
Hirsutism, in polycystic ovarian syndrome, 222, 229
HIV infections, diabetes mellitus due to, 10–11
HNF gene mutations, 6–7
Human insulin, 165, 168–170
Hyperandrogenism, in polycystic ovarian syndrome, 221–235
Hyperglycemia
   idiopathic. See Diabetes mellitus, type 2.
   toxicity of, 4–5
Hyperglycemia and Adverse Pregnancy Outcome study, 5–6
Hyperkalemia, 190
Hypertension, 188–191, 202–204
Hypertension in the Very Elderly trial, 190
Hypoglycemia
   in insulin therapy, 147–152, 179–180
   internet blood glucose monitoring systems effects on, 25

I
Idiopathic hyperglycemia. See Diabetes mellitus, type 2.
Imipramine, 208
Immunology of Diabetes Society, 4
Incretin-based therapy, 107–129
   cardiovascular safety of, 122–123
   incretin effect in, 108
   options for, 108–121
Infertility, in polycystic ovarian syndrome, 222
Insulin. See also Insulin therapy.
analog preparations, 170
basal, 148–149, 171, 173
bolus, 148, 173–178
Insulin aspart, 148, 166–168
Insulin degludec, 167–168
Insulin detemir, 147–148, 167–168
Insulin glargine, 147–148, 167–168
Insulin glulisine, 148, 168
Insulin lispro, 148, 166–168
Insulin resistance
  in diabetes mellitus, 4–5
  in polycystic ovarian syndrome, 221–232
  in pregnancy, 5–6
Insulin secretogogues, 90–93
Insulin stacking, 149, 177–178
Insulin therapy, 145–156
  adverse effects of, 179–180
  basal insulin formulations for, 148–149, 171, 173
  bolus, 148, 173–178
  closed-loop delivery of, 42
  deescalating of, 180–181
  delivery devices for, 171–172
  dosing regimens for, 149–150
  education for, 152–153
  for type 1 diabetes mellitus, 145–156
  for type 2 diabetes mellitus, 157–186
  guidelines for, 182
  highly concentrated, 171, 178–179
  human, 165, 168–170
  initiation of, 161–164, 171, 173–179
  insulin production physiology and, 158–160
  intensive, 37, 151
  intermediate-acting, 168–170
  long-acting, 168, 170
  options for, 146–152
  pharmacokinetics of, 166–167
  premixed, 167, 170, 178
  preparations for, 165–171
  production of, physiology of, 158–160
  pumps for, 150–151, 172, 179
  rapid-acting, 168, 170
  short-acting, 168–169
  strategy for, 146
  team approach to, 152–153, 182
Insulin:Carbohydrate Ratio, 175–177
Intensive insulin therapy, 37, 151
Intermediate-acting insulin, 168–170
International A1c-Derived Average Glucose trial, 36
International Statistical Classification of Diseases and Related Health Problems, 11
Internet blood glucose monitoring system, 17–33
  cardiovascular risk and, 26
Index

Internet (continued)
clinical studies of, 17–26
cost-effectiveness of, 27
hypoglycemia and, 25
implementation statistics for, 28
mechanisms for, 25–26
practical tips for, 29
quality of life with, 26–27
Iprafilflozin, 140
ISIS 388626, 140

J
Joint National Committee guidelines, for hypertension, 189–190
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study, 40, 153

K
KCNJ11 gene mutations, 6–7
KDIGO (Kidney Disease Improving Global Outcomes), 189–190
Ketosis, in diabetes mellitus type 2, 5
Kidney
dysfunction of, 48–50, 54, 188–191, 209–212
glucose regulation in, 132–134
Kidney Disease Improving Global Outcomes (KDIGO), 189–190
Kumamoto study, 56–58, 60

L
Lactic acidosis, metformin-induced, 89–90
Latent autoimmune diabetes of adults, 3–4
Letrozole, for polycystic ovarian syndrome, 230
Lidocaine, 208–209
Lifestyle interventions, 69–85, 204
nutrition therapy, 71–80, 203
outcome of, 76
physical activity, 72–80, 204
priorities in, 76–80
resistance to, 74
Linagliptin, 118, 120–122, 181
Lipid targets, 191–192, 203–204
Lipotoxicity, in diabetes mellitus, 4–5
Liraglutide, 110–111, 113–114, 122, 181
Long-acting insulin, 168, 170
Look AHEAD trial, 193
Luteinizing hormone, in polycystic ovarian syndrome, 224–225
LX 4211, 140

M
Macrovascular disease, 50–52
Mammalian target of rapamycin inhibitors, 9
Maturity-onset diabetes of the young (MODY), 6–7
Medical nutrition therapy, 71–80
Menopause, polycystic ovarian syndrome in, 232
Menstrual abnormalities, in polycystic ovarian syndrome, 222
Mental health disorders, 193
MET Plus approach, 161–162
Metabolic syndrome, in polycystic ovarian syndrome, 223
Metformin, 88–90, 99, 161–162, 181
Microvascular disease, 48–50
Miglitol, 181
Mitochondrial diabetes mellitus, 7
MODY-like diabetes, 6–7
Monitoring, blood glucose. See Blood glucose monitoring.
Monogenic diabetes, 6–7
Multiple Risk Factor Intervention Trial, 50

N
Nateglinide, 92–93, 99, 181
National Glycohemoglobin Standardization Program, 36
NAVIGATOR trial, 192
Neonatal diabetes mellitus, 6–7
Nephropathy, 48–50, 54, 188–191, 209–212
Neuropathy, peripheral, 48–40, 79, 206–209
Neutral protamine Hagedorn insulin, 147–148, 166–170
Nortriptyline, 208
Nutrition therapy, 71–80, 203

O
Obesity, 193–196
   in polycystic ovarian syndrome, 223, 230
   weight loss for, 71–80, 193–196, 231
Olanzapine, diabetes mellitus due to, 9
Oligomenorrhea, in polycystic ovarian syndrome, 222
Ophthalmoscopy, for retinopathy, 205
Oral antihypoglycemics, 87–106
   alpha-glucosidase inhibitors, 97, 99, 181
   bromocriptine mesylate, 98–99, 181
   colesevelam, 97–98, 181
   glinides, 92–93, 99, 181
   metformin, 88–90, 99, 161–162, 181
   sodium-glucose transporter type 2 inhibitors, 95–96, 131–143
   sulfonylureas, 90–92
   thiazolidinediones, 93–95
Oral contraceptives, for polycystic ovarian syndrome, 228–229
Ovarian theca cell abnormalities, in polycystic ovarian syndrome, 225
Ovary, polycystic disease of, 221–235
Ovulation, induction of, for polycystic ovarian syndrome, 230
Oxycodone, 208
P

Pain, in peripheral neuropathy, 206–209
Pancreas, disorders of, 7–8
Pancreatectomy, 8
Pancreatitis, 8
Patch, insulin, 172
Patient Health Questionnaire, 193
Pens, for insulin delivery, 172
Personal continuous glucose monitoring, 40–41
Photography, digital retinal, 205
Physical activity, 72–80, 204
Pioglitazone, 93–95, 99, 181
Polycystic ovarian syndrome, 221–235
  cardiovascular risks in, 231
  clinical presentation of, 221–224
  diagnosis of, 225–226
  differential diagnosis of, 228
  endometrial protection in, 230
  evaluation of, 226–227
  genetics of, 225
  in adolescents, 231
  in menopause, 232
  infertility management in, 230–231
  pathophysiology of, 224–225
  treatment of, 228–229
Pramlintide, 181
Pregabalin, 208–209
Pregnancy
  diabetes mellitus in, 5–6
  in polycystic ovarian syndrome, 230–231
  retinopathy in, 205
Premixed insulin, 167, 170, 178
Problem Areas in Diabetes Questionnaire, 193
Professional continuous glucose monitoring, 40
Prospective Pioglitazone Clinical Trial in the Macrovascular Events, 60, 94
Proteinuria, 190
Pumps, for insulin delivery, 150–151, 172, 179

Q

Quality of life, internet blood glucose monitoring systems effects on, 26–27
Quetiapine, diabetes mellitus due to, 9

R

Rapid-acting insulin, 168
Real-time continuous glucose monitoring, 41–42
RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent
  Combination Therapy for Type 2 Diabetes) trial, 94
Registered dietitians, in nutrition therapy, 70–80
Repaglinide, 92–93, 99, 181
Retinopathy, 48–50, 54, 204–206
Risperidone, diabetes mellitus due to, 9
Rosiglitazone, 93–95, 99, 181
Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD) trial, 94
Rotterdam criteria, for polycystic ovarian syndrome, 225–226

S
Saxagliptin, 118–120, 122, 181
Self-monitored glycemic control
  in type 2 diabetes mellitus, 164–165
  internet system for, 17–33
  methods for, 37–39
Short-acting insulin, 168–169
Sirolimus, diabetes mellitus due to, 9
Sitagliptin, 118–119, 122, 181
Sleep apnea, in polycystic ovarian syndrome, 224
Sodium glucose cotransporter 2 inhibitors, 95–96, 99, 131–143
  adverse events due to, 135
  1,5-anhydroglucitrol measurement interference from, 140
  cardiovascular outcomes of, 139–140
  drug interactions with, 139
  in development stage, 140
  in kidney disease, 138
  kidney function and, 132–134
  mechanism of action of, 134–135
  options for, 135–138
Spironolactone, for polycystic ovarian syndrome, 229
STAR3 study, 40–41
Statins, 10, 192, 203
Sulfonylureas, 90–92, 99, 181
Syringes, for insulin delivery, 172

T
Tacrolimus, diabetes mellitus due to, 9
T1D Exchange Registry, 151
Team approach, to insulin therapy, 152–153
Thiazides, diabetes mellitus due to, 10
Thiazolidinediones, 93–95, 99, 181
Tolbutamide, 91
Tramadol, 208
Transcutaneous electrical nerve stimulation, 209
Triglyceride reduction, 203
Tumors, pancreatic, 8

U
UKPDS (United Kingdom Prospective Diabetes Study), 3–5, 36, 53–56, 58–60, 89, 202, 205–206, 209
Ultrasonography, for polycystic ovarian syndrome, 227
United Kingdom Prospective Diabetes Study (UKPDS), 3–5, 36, 53–56, 58–60, 89, 202, 205–206, 209
University Group Diabetes Project, 91

V
VADT (Veterans Affairs Diabetes Trial), 57–61
Vascular endothelial growth factors, in retinopathy, 206
Venlafaxine, 208
Veterans Affairs Diabetes Trial (VADT), 57–61
Vidagliptin, 181
Virilization, in polycystic ovarian syndrome, 222

W
Weight loss, 71–80, 193–196, 231
Well-Being Index, 193
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 48, 204
Wolfram syndrome, 7

Z
Ziprasidone, diabetes mellitus due to, 9